Cothera Receives Authorization from the FDA to Conduct a Phase 2 Clinical Trial to Test Its Targeted MYC Mutation Inhibitor PC-002 for the Treatment of High-Grade B-cell Lymphoma

Cothera Bioscience today announced that it has received approval from the U.S. Food and Drug Adminis...

Cothera Bioscience completes series-B financing of 30 million dollars, aiming at innovative anti-tumor drugs

We will continue to base ourselves on the development of the world’s first-in-class drugs...

Personalized Tumor Drug Susceptibility Testing Platform by Percans Oncology

Percans Oncology has developed i-CR, a personalized drug susceptibility testing platform for the pre...